Market requirements · CH
Switzerland
Swissmedic regulates therapeutic products under the Heilmittelgesetz and runs a named, active cross-agency programme intercepting inbound peptide shipments.
| Tell us the compounds you need for Switzerland. | Ask about Switzerland |
The regime
How compounds are classified in Switzerland
| Governing law and regulator | Swissmedic regulates therapeutic products under the Heilmittelgesetz (HMG). It jointly runs a named, active cross-agency programme, "Schwerpunktaktion Peptide 2026," with Swiss customs (BAZG) and Swiss Sport Integrity. |
|---|---|
| What the regulator stated | Swissmedic explicitly warns against ordering peptides from unknown online, social-media, or messenger sources. In June 2026 the joint action inspected and stopped 46 shipments of what it describes as dubious peptide preparations entering Switzerland from abroad. |
| Prescription-only compounds | Swissmedic's own warning states semaglutide and tirzepatide are prescription-only medicines available legally only through medical distribution channels, and explicitly says the "Research Chemical" label offers no legal protection. It notes illegal suppliers sourcing active substances from Asia with no pharmaceutical control. |
| HGH specifically | Under the HMG, growth hormones sit in prescription release category A, a stricter tier requiring a Swiss-registered physician's prescription before every dispensing rather than once at the outset. Distribution without one is illegal. |
| Melanotan and enforcement posture | Switzerland generally allows personal import of small quantities of medicines unapproved in Switzerland, but this exemption does not apply to doping substances, which carry zero personal allowance. Melanotan's exact classification on this line was not confirmed by a single definitive Swissmedic statement, so the precise personal-import threshold is unverified - though this is largely moot for a commercial wholesale supplier, since the personal-use exemption never applies to B2B sales regardless of classification. |
| Already supplying Switzerland? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in Switzerland needs settled
- Do not market any compound as a research chemical for the Swiss market - Swissmedic explicitly states this label offers no legal protection.
- Expect physical shipment interdiction - Swissmedic, BAZG customs, and Swiss Sport Integrity are actively and jointly screening inbound peptide shipments as of 2026.
- Assume HGH requires a Swiss physician's prescription for every dispensing, not a one-time authorisation, and do not position it as a wholesale RUO product.
- Do not rely on any personal-use import allowance for commercial supply - it does not apply to a B2B seller under any compound classification.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| Swissmedic Warning on GLP-1 products (semaglutide/tirzepatide) | undated | www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/mar... |
| Swissmedic Schwerpunktaktion Peptide 2026 - cross-agency shipment interdiction programme | June 2026 | www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/mar... |
| Swissmedic Legal basis for therapeutic products in Switzerland | undated | www.swissmedic.ch/swissmedic/en/home/legal/legal-basis/rec... |
| Tages-Anzeiger Secondary press coverage of Swissmedic stopping 46 dubious shipments | June 2026 | www.tagesanzeiger.ch/peptide-swissmedic-stoppt-46-dubiose-... |
| Rentsch Partner Secondary legal-firm commentary on Swiss therapeutic products law (Heilmittelrecht) | undated | www.rentschpartner.ch/industrial-law/heilmittelrecht |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the Switzerland brief as a PDF
The regime, the buyer obligations and all 5 sources, dated and linked, in one document you can forward.
Nearby
German-speaking markets and nearby markets
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| DE | Germany | 2 sources | Germany applies the Arzneimittelgesetz alongside anti-doping legislation, and ... |
| AT | Austria | 3 sources | BASG has published a dedicated position holding that a research-use label does... |
| BE | Belgium | 3 sources | Belgium applies EU medicines law through the FAGG, which has published a GLP-1... |
| DK | Denmark | 5 sources | Laegemiddelstyrelsen maintains standing warnings, including on Melanotan. Rese... |
Scope
How to use this page
A summary of the published regulatory position in Switzerland as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into Switzerland
Do you supply into Switzerland?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Switzerland depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into Switzerland. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into Switzerland
Tell us the compounds and your authorisations. We confirm per compound before anything ships.